Four Years After Covid-19 Success, mRNA Vaccines Aren’t Ready for Bird Flu
While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.
FierceBiotech3d
GSK, Merck and Pfizer in Ab&B's sights as Chinese vaccine biotech files for IPO
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
pharmaphorum3d
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief
GSK said at an R&D update in the summer that it expects to have two mRNA candidates in clinical trials within 12 months and six within the next four years, including seasonal flu shots.
FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
Business Insider19d
Moderna and other vaccine maker shares jump after first US bird flu death
Moderna, Pfizer, and a partnership between GSK and CureVac are reportedly working ... and Prevention reported the first death from bird flu on Monday, announcing an elderly patient with underlying ...
BioPharma Dive5d
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...
Yahoo Finance18d
Moderna stock forfeits gains as first US bird flu death puts vaccine development in focus
CureVac is developing an mRNA bird flu shot in collaboration with London-based pharma giant GlaxoSmithKline (GLAXO.BO). Pfizer stock (PFE) ticked up a much more modest 0.9%, while GSK itself ...